<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel>
        <title>Health &amp; BioTech Dispatches | BlogBuckett</title>
        <link>https://www.blogbuckett.page/category/health</link>
        <description>Biotechnology breakthroughs, digital health, AI-driven drug discovery, genomic sequencing, and medical technology.</description>
        <lastBuildDate>Wed, 12 Aug 2026 03:03:11 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>https://github.com/jpmonette/feed</generator>
        <language>en</language>
        <copyright>All rights reserved 2026, BlogBuckett</copyright>
        <item>
            <title><![CDATA[Beyond Single-Gene Testing: How Multi-Omic Proteogenomic Benchmarks Are Overcoming Immunotherapy Resistance]]></title>
            <link>https://www.blogbuckett.page/blog/health/2026-08-11-beyond-single-gene-testing-how-multi-omic-proteogenomic-benchmarks-are-overcoming-immunotherapy-resistance</link>
            <guid isPermaLink="false">https://www.blogbuckett.page/blog/health/2026-08-11-beyond-single-gene-testing-how-multi-omic-proteogenomic-benchmarks-are-overcoming-immunotherapy-resistance</guid>
            <pubDate>Tue, 11 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Integrating spatial transcriptomics, chromatin accessibility, and quantitative proteomics into unified diagnostic matrices is redefining clinical trial endpoints and overcoming refractory tumor resistance.]]></description>
            <content:encoded><![CDATA[Integrating spatial transcriptomics, chromatin accessibility, and quantitative proteomics into unified diagnostic matrices is redefining clinical trial endpoints and overcoming refractory tumor resistance.]]></content:encoded>
            <enclosure url="https://images.unsplash.com/photo-1584515979956-d9f6e5d09982?auto=format&amp;fit=crop&amp;w=1200&amp;q=80" length="0" type="image//photo-1584515979956-d9f6e5d09982"/>
        </item>
        <item>
            <title><![CDATA[Atomic Precision Therapeutics: How Equivariant Diffusion and Cryo-EM Are Unlocking Undruggable Membrane Receptors]]></title>
            <link>https://www.blogbuckett.page/blog/health/2026-08-11-atomic-precision-therapeutics-how-equivariant-diffusion-and-cryo-em-are-unlocking-undruggable-membrane-receptors</link>
            <guid isPermaLink="false">https://www.blogbuckett.page/blog/health/2026-08-11-atomic-precision-therapeutics-how-equivariant-diffusion-and-cryo-em-are-unlocking-undruggable-membrane-receptors</guid>
            <pubDate>Tue, 11 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Integrating sub-2-Angstrom Cryo-EM target profiling with 3D SE(3)-equivariant diffusion models is enabling direct, de novo synthesis of high-affinity antibodies against historically intractable GPCRs and multipass ion channels.]]></description>
            <content:encoded><![CDATA[Integrating sub-2-Angstrom Cryo-EM target profiling with 3D SE(3)-equivariant diffusion models is enabling direct, de novo synthesis of high-affinity antibodies against historically intractable GPCRs and multipass ion channels.]]></content:encoded>
            <enclosure url="https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?auto=format&amp;fit=crop&amp;w=1200&amp;q=80" length="0" type="image//photo-1576091160399-112ba8d25d1d"/>
        </item>
        <item>
            <title><![CDATA[Mapping the Tumor Microenvironment: How Spatial Transcriptomics and Multi-Omics Are Redefining Precision Oncology Benchmarks]]></title>
            <link>https://www.blogbuckett.page/blog/health/2026-08-10-mapping-the-tumor-microenvironment-how-spatial-transcriptomics-and-multi-omics-are-redefining-precision-oncology-benchmarks</link>
            <guid isPermaLink="false">https://www.blogbuckett.page/blog/health/2026-08-10-mapping-the-tumor-microenvironment-how-spatial-transcriptomics-and-multi-omics-are-redefining-precision-oncology-benchmarks</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[By resolving gene expression down to sub-cellular coordinates, single-cell spatial transcriptomics is illuminating hidden immunosuppressive niches within solid tumors. Discover how multi-omic diagnostic pipelines are doubling predictive accuracy for immunotherapy response.]]></description>
            <content:encoded><![CDATA[By resolving gene expression down to sub-cellular coordinates, single-cell spatial transcriptomics is illuminating hidden immunosuppressive niches within solid tumors. Discover how multi-omic diagnostic pipelines are doubling predictive accuracy for immunotherapy response.]]></content:encoded>
            <enclosure url="https://images.unsplash.com/photo-1579684385127-1ef15d508118?auto=format&amp;fit=crop&amp;w=1200&amp;q=80" length="0" type="image//photo-1579684385127-1ef15d508118"/>
        </item>
        <item>
            <title><![CDATA[Breaking the Delivery Bottleneck: Targeted Non-Viral Vectors and Automated Cell Synthesis Bring In Vivo CRISPR to Mainstream Clinical Medicine]]></title>
            <link>https://www.blogbuckett.page/blog/health/2026-08-10-breaking-the-delivery-bottleneck-targeted-non-viral-vectors-and-automated-cell-synthesis-bring-in-vivo-crispr-to-mainstream-clinical-medicine</link>
            <guid isPermaLink="false">https://www.blogbuckett.page/blog/health/2026-08-10-breaking-the-delivery-bottleneck-targeted-non-viral-vectors-and-automated-cell-synthesis-bring-in-vivo-crispr-to-mainstream-clinical-medicine</guid>
            <pubDate>Mon, 10 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Emerging targeted lipid nanoparticles and automated high-throughput microfluidic platforms are overcoming the historical limitations of viral vectors in gene editing. Explore how these technological breakthroughs are enabling precise, scalable in vivo CRISPR therapeutics for genetic disorders.]]></description>
            <content:encoded><![CDATA[Emerging targeted lipid nanoparticles and automated high-throughput microfluidic platforms are overcoming the historical limitations of viral vectors in gene editing. Explore how these technological breakthroughs are enabling precise, scalable in vivo CRISPR therapeutics for genetic disorders.]]></content:encoded>
            <enclosure url="https://images.unsplash.com/photo-1530497610245-94d3c16cda28?auto=format&amp;fit=crop&amp;w=1200&amp;q=80" length="0" type="image//photo-1530497610245-94d3c16cda28"/>
        </item>
        <item>
            <title><![CDATA[The Zero-Shot Therapeutic Epoch: How Generative AI De Novo Antibody Design Just Passed Phase II Clinical Benchmarks]]></title>
            <link>https://www.blogbuckett.page/blog/health/2026-08-09-the-zero-shot-therapeutic-epoch-how-generative-ai-de-novo-antibody-design-just-passed-phase-ii-clinical-benchmarks</link>
            <guid isPermaLink="false">https://www.blogbuckett.page/blog/health/2026-08-09-the-zero-shot-therapeutic-epoch-how-generative-ai-de-novo-antibody-design-just-passed-phase-ii-clinical-benchmarks</guid>
            <pubDate>Sun, 09 Aug 2026 00:00:00 GMT</pubDate>
            <description><![CDATA[Generative AI-designed protein therapeutics have reached a historic milestone in human trials, showing unprecedented target affinity and drastically reduced immunogenicity in refractory oncology patients. Here is an analysis of the clinical trial data, pipeline architecture, and future patient outcomes.]]></description>
            <content:encoded><![CDATA[Generative AI-designed protein therapeutics have reached a historic milestone in human trials, showing unprecedented target affinity and drastically reduced immunogenicity in refractory oncology patients. Here is an analysis of the clinical trial data, pipeline architecture, and future patient outcomes.]]></content:encoded>
            <enclosure url="https://images.unsplash.com/photo-1532187863486-abf9dbad1b69?auto=format&amp;fit=crop&amp;w=1200&amp;q=80" length="0" type="image//photo-1532187863486-abf9dbad1b69"/>
        </item>
    </channel>
</rss>